Continuous Glucose Monitorization in Hospitalized Patients With COVID-19

Recruiting

• Conditions: Diabetes Mellitus; Covid19

• Registration Number: NCT05096858
• Lead Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Brief Summary

DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics.

In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-01
• Study First Submitted: 2021-09-13
• Study First Submitted QC: 2021-10-25
• Study First Posted: 2021-10-27
• Status Verified: 2023-09
• Last Update Submitted: 2024-03-07
• Last Update Posted: 2024-03-08
• Primary Completion: 2024-06-30
• Study Completion: 2024-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Confirmed COVID-19 pneumonia
• Diabetes mellitus

Exclusion Criteria

• Less than 3 days of hospital care

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin use	For up two weeks, during hospitalization	Average daily UI of insulin per patient
Glucose variability	For up to two weeks, during hospitalization	Percentage of time within the ADA recommended range

Trial Locations

Locations (1)

National Institute of Medical Sciences and Nutrition Salvador Zubiran; 🇲🇽 Mexico City, Mexico